In a single-center cohort of 392 patients with low-risk branch-duct IPMNs (BD-IPMNs) followed for a median of 67 months (2375 person-years total), the study tested published 'trivial' criteria for stopping surveillance after 5 years of stability — specifically, age ≥75 with cyst <30 mm, or age ≥65 with cyst ≤15 mm — measuring how many high-grade lesions would be missed and what resources would be released across 14 health systems.
Applying the discontinuation criteria would have discharged 101 patients (25.8%) with no high-grade dysplasia or invasive carcinoma missed, releasing 298 person-years and €79,316 per 1,000 patients entering surveillance; the upper 95% bound of the undetected high-grade lesion rate was 0.84 per 100 person-years, and the same rule released €42,000–€170,000 per 1,000 patients depending on which health system's tariffs were used.
Single-center retrospective cohort (n=101 discharged, 298 person-years released) is too small to exclude a clinically relevant rate of missed high-grade lesions (upper 95% bound 0.84/100 person-years); only 67% of protocol-intended cross-sectional exams were performed, potentially reducing sensitivity for detecting progression; cost analysis takes the payer perspective only, omitting patient time, travel, psychological burden, and outpatient visits.
Stopping BD-IPMN surveillance after 5 stable years in patients aged ≥75 (cyst <30 mm) or ≥65 (cyst ≤15 mm) appeared safe in this external cohort, but cannot yet be considered proven — the economic benefit is modest and highly dependent on local imaging costs and actual surveillance delivery rates, so institutions should recalculate savings locally before citing published figures.
Explore related topics